{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 177,
  "pageCount": 239,
  "prevPage": 176,
  "nextPage": 178,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses expert testimony to undermine the credibility of the CEO and the company's strategic direction.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/177",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-177",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We note that one executive after another we spoke with described Grossman as a quick-flip artist who now finds himself in an uncomfortable position.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b345-fad883d83ccc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "A second former executive, in touch with the management team and now in a senior role at a key competitor, provided a similarly damning view of Grossman’s turnaround, describing his understanding of the SCS space as “naïve.” He shared his sense from members of the management team that Grossman is “busy on a lot of others things” and questioned who’s running Nevro day to day, given that he failed to deliver a quick flip and now finds himself in a role he didn’t expect. We note that one executive after another we spoke with described Grossman as a quick-flip artist who now finds himself in an uncomfortable position. The former executive also described an ongoing collapse of Nevro’s international business.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2940e84e-ad3d-4cf8-93e1-a6387eb99b65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.59
      },
      "kind": "quote",
      "text": "“I also got a sense this wasn’t a role that he was expecting and that he’s very busy on a lot of other things he’s doing. A lot of other things, and I don’t know how much attention - I mean obviously he’s spending a lot of time on Nevro - but I think there are other people who are running the ship largely and that’s sort of the sense I got from these people on the leadership team” – Former Nevro executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a687201-26db-4748-b501-442b17218df4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.9,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "quote",
      "text": "“Keith is definitely a more polished individual but his understanding of the technology that he’s speaking to, and the way that’s going to be received by physicians, is naïve. Grossman describes Omnia as really just the marketing, like the same marketing spin that was being presented at NANS. I don’t think he understands the way that these physicians work and their desire to have new and innovative products. Omnia is not a new or innovative product. It’s basically just a repackaging of an old product.” – Former Nevro executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "968a340a-d28f-40c0-a59f-da2728f83068",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.77
      },
      "kind": "quote",
      "text": "“Three key people, including the person responsible for all of global, have been taken out of the organization and about four weeks later two key people in the European area left the organization. So now there’s a fairly junior leadership team within the European organization.” – Former Nevro executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddb0d8bc-35e6-4660-9d94-fee468adabd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Keith is definitely a more polished individual but his understanding of the technology that he’s speaking to, and the way that’s going to be received by physicians, is naïve. Grossman describes Omnia as really just the marketing, like the same marketing spin that was being presented at NANS. I don’t think he understands the way that these physicians work and their desire to have new and innovative products. Omnia is not a new or innovative product. It’s basically just a repackaging of an old product. — Former Nevro executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b345-fec1c2d91fae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55082d09-6b1a-4148-aa99-579774dd713f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "12. Investors betting on a Keith Grossman-driven turnaround will shortly face a rude awakening",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3f82896-5f02-417d-9fd7-d01387c47190",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81fac205-e859-45ab-aa61-491b1495bf33",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}